Product Description
Type II JAK2 Inhibitor administred orally. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06343805)
Mechanisms of Action: JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ajax Therapeutics, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential|Thrombocytosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JAK2i | P1 |
Recruiting |
Polycythemia Vera|Myelofibrosis|Thrombocythemia, Essential|Thrombocytosis |
2026-10-15 |